29.52
0.63 (2.18%)
| Previous Close | 28.89 |
| Open | 29.07 |
| Volume | 339,479 |
| Avg. Volume (3M) | 1,473,390 |
| Market Cap | 3,125,236,224 |
| Price / Book | 5.56 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Diluted EPS (TTM) | -1.55 |
| Total Debt/Equity (MRQ) | 1.06% |
| Current Ratio (MRQ) | 20.99 |
| Operating Cash Flow (TTM) | -118.30 M |
| Levered Free Cash Flow (TTM) | -67.74 M |
| Return on Assets (TTM) | -21.08% |
| Return on Equity (TTM) | -30.29% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Edgewise Therapeutics, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | -3.0 |
| Price Volatility | -3.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 4.0 |
| Average | -0.40 |
|
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company’s product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.42% |
| % Held by Institutions | 104.04% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 50.00 (RBC Capital, 69.38%) | Buy |
| Median | 34.00 (15.18%) | |
| Low | 32.00 (Wedbush, 8.40%) | Buy |
| Average | 38.67 (31.00%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 19.02 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 14 Nov 2025 | 34.00 (15.18%) | Buy | 22.75 |
| RBC Capital | 07 Nov 2025 | 50.00 (69.38%) | Buy | 17.16 |
| Wedbush | 07 Nov 2025 | 32.00 (8.40%) | Buy | 17.16 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |